Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

BACKGROUND: Synucleinopathies such as Parkinson ´s disease (PD), Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA) are characterized by deposition of misfolded and aggregated α-synuclein. Small aggregates (oligomers) of α-synuclein have been shown to be the most relevant neurotoxic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Johannes, Sing, Nand, Melbourne, Sue, Morgan, Amber, Mariner, Carla, Spillantini, Maria Grazia, Wegrzynowicz, Michal, Dalley, Jeffrey W., Langer, Simon, Ryazanov, Sergey, Leonov, Andrei, Griesinger, Christian, Schmidt, Felix, Weckbecker, Daniel, Prager, Kai, Matthias, Torsten, Giese, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065877/
https://www.ncbi.nlm.nih.gov/pubmed/35500536
http://dx.doi.org/10.1016/j.ebiom.2022.104021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065877/
https://www.ncbi.nlm.nih.gov/pubmed/35500536
http://dx.doi.org/10.1016/j.ebiom.2022.104021

Ejemplares similares